Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs

In what’s shap­ing up to be an­oth­er slow year for biotech IPOs — bet­ter, how­ev­er, than the 2022 and 2023 dol­drums — Jim Healy is some­what of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.